Table of Contents

December 18, 2007; 147 (12)

Articles

  • An Externally Validated Model for Predicting Long-Term Survival after Exercise Treadmill Testing in Patients with Suspected Coronary Artery Disease and a Normal Electrocardiogram

    • Michael S. Lauer,
    • Claire E. Pothier,
    • David J. Magid,
    • S. Scott Smith,
    • and Michael W. Kattan
    Ann Intern Med December 18, 2007 147:821-828

    In a large prospective cohort study, Lauer and colleagues developed a post–treadmill test prediction rule to determine mortality in adults with normal electrocardiograms and suspected coronary artery disease. Their model used clinical and treadmill variables coupled with a nomogram to predict all-cause mortality. The nomogram better discriminated between those who die and those who survive than did the standard Duke treadmill score, which uses only treadmill test variables to predict outcome. It gave good results when used to predict all-cause mortality in an independent population of patients from a large HMO.

  • Non-HACEK Gram-Negative Bacillus Endocarditis

    • Susan Morpeth,
    • David Murdoch,
    • Christopher H. Cabell,
    • Adolf W. Karchmer,
    • Paul Pappas,
    • Donald Levine,
    • Francisco Nacinovich,
    • Pierre Tattevin,
    • Núria Fernández-Hidalgo,
    • Stuart Dickerman,
    • Emilio Bouza,
    • Ana del Río,
    • Tatjana Lejko-Zupanc,
    • Auristela de Oliveira Ramos,
    • Diana Iarussi,
    • John Klein,
    • Catherine Chirouze,
    • Roger Bedimo,
    • G. Ralph Corey,
    • Vance G. Fowler, Jr.,
    • and the International Collaboration on Endocarditis Prospective Cohort Study (ICE-PCS) Investigators*
    Ann Intern Med December 18, 2007 147:829-835

    Endocarditis caused by non-HACEK organisms (species other than Haemophilus species, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella species) has long been thought to be associated with injection drug use. Morpeth and coworkers described the clinical characteristics and outcomes of 2761 cases of patients with infective endocarditis from 61 hospitals. Non-HACEK organisms accounted for fewer than 2% of cases. Most non-HACEK endocarditis infections were associated with health care: 59% of patients had implanted endovascular devices or prosthetic valves and only 4% were injection drug users. More than half of the patients with non-HACEK infections had cardiac surgery; 24% died.

  • Brief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease

    • Mark Bower,
    • Tom Powles,
    • Sarah Williams,
    • Tom Newsom Davis,
    • Mark Atkins,
    • Silvia Montoto,
    • Chloe Orkin,
    • Andy Webb,
    • Martin Fisher,
    • Mark Nelson,
    • Brian Gazzard,
    • Justin Stebbing,
    • and Peter Kelleher
    Ann Intern Med December 18, 2007 147:836-839

    Rituximab has shown some therapeutic promise in patients with Castleman disease previously treated with chemotherapy, but we lack data on initial therapy with rituximab. This uncontrolled case series suggests that initial treatment with rituximab can achieve better overall and disease-free survival than that anticipated in untreated patients (overall and disease-free survival rates at 2 years were 95% and 79%, respectively). Laboratory measures of disease activity also improved with therapy. Because the study lacked a concurrent control group, we must wait for definitive assessment of the efficacy or safety of this therapy.

Academia and Clinic

  • Update on the Methods of the U.S. Preventive Services Task Force: Estimating Certainty and Magnitude of Net Benefit

    • George F. Sawaya,
    • Janelle Guirguis-Blake,
    • Michael LeFevre,
    • Russell Harris,
    • Diana Petitti,
    • and for the U.S. Preventive Services Task Force
    Ann Intern Med December 18, 2007 147:871-875

    The major goal of the U.S. Preventive Services Task Force is to provide reliable and accurate evidence-based recommendations on a wide range of preventive services. In this article, the Task Force describes its current, updated process for evaluating evidence, determining the certainty and magnitude of net benefit, and assigning a final letter grade to recommendations.

  • Caring for Organs or for Patients? Ethical Concerns about the Uniform Anatomical Gift Act (2006)

    • Michael A. DeVita and
    • Arthur L. Caplan
    Ann Intern Med December 18, 2007 147:876-879

    The National Conference on Uniform State Laws modified the Uniform Anatomical Gift Act (2006) to prevent care at the end of life from precluding organ donation. The new language has the unintended consequence of giving higher priority to care of the potential donor organs than the dying person. The act has been revised, but many states have enacted the original version into law. DeVita and Caplan discuss the reason for updating the act; the ethical concerns involved; and the lessons to be learned from the failure to recognize an important and long-standing ethical boundary: the protected status of a physician's orders and a patient's wishes.

Review

  • Meta-analysis: Vitamin D Compounds in Chronic Kidney Disease

    • Suetonia C. Palmer,
    • David O. McGregor,
    • Petra Macaskill,
    • Jonathan C. Craig,
    • Grahame J. Elder,
    • and Giovanni F.M. Strippoli
    Ann Intern Med December 18, 2007 147:840-853

    Most patients with advanced kidney disease take vitamin D compounds to prevent secondary hyperparathyroidism. Palmer and colleagues' meta-analysis of 76 randomized trials found no good evidence that vitamin D compounds reduced risk for death, bone pain, vascular calcification, or need for parathyroidectomy in patients with chronic kidney disease (CKD). Compared with placebo, older vitamin D sterols increased the risk for hypercalcemia and hyperphosphatemia, whereas newer vitamin D analogues increased the risk for hypercalcemia but not hyperphosphatemia. Direct comparisons between newer analogues and established agents found no advantage to newer drugs. Vitamin D compounds do not reduce adverse outcomes in CKD and might increase them.

Clinical Guidelines

  • Screening for Carotid Artery Stenosis: U.S. Preventive Services Task Force Recommendation Statement

    • U.S. Preventive Services Task Force
    Ann Intern Med December 18, 2007 147:854-859

    In this update to a previous recommendation, the U.S. Preventive Services Task Force recommends that clinicians not screen for asymptomatic carotid artery stenosis in the general adult population. This recommendation applies to adults without neurologic signs or symptoms or a history of transient ischemic attacks or stroke.

  • Screening for Carotid Artery Stenosis: An Update of the Evidence for the U.S. Preventive Services Task Force

    • Tracy Wolff,
    • Janelle Guirguis-Blake,
    • Therese Miller,
    • Michael Gillespie,
    • and Russell Harris
    Ann Intern Med December 18, 2007 147:860-870

    This evidence update supports the U.S. Preventive Services Task Force recommendations on screening for carotid artery stenosis.

Editorial

  • Vitamin D in Patients with Chronic Kidney Disease: Nothing New under the Sun

    • Marcello Tonelli
    Ann Intern Med December 18, 2007 147:880-881

    Palmer and colleagues' meta-analysis in this issue synthesizes data from 76 trials evaluating the clinical benefits of vitamin D supplementation in 3776 patients with CKD. The results will surprise many physicians who care for patients with CKD: The evidence does not support the current widespread use of vitamin D in CKD.

Letters

  • Estimating Net Benefits and Harms of Screening Mammography in Women Age 40 to 49 Years

    • Benjamin Djulbegovic,
    • Iztok Hozo,
    • and Gary H. Lyman
    Ann Intern Med December 18, 2007 147:882

  • Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone–Salmeterol for Chronic Obstructive Pulmonary Disease: Possible Confounding Effect of Treatment Withdrawal?

    • Samuel M. Brown
    Ann Intern Med December 18, 2007 147:882

  • Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone–Salmeterol for Chronic Obstructive Pulmonary Disease: Possible Confounding Effect of Treatment Withdrawal?

    • Shawn D. Aaron
    Ann Intern Med December 18, 2007 147:882-883

  • Chondroitin for Osteoarthritis of the Knee or Hip

    • Harley Goldberg,
    • Andrew Avins,
    • and Stephen Bent
    Ann Intern Med December 18, 2007 147:883

  • Chondroitin for Osteoarthritis of the Knee or Hip

    • Jean-Pierre Pelletier
    Ann Intern Med December 18, 2007 147:883-884

  • Chondroitin for Osteoarthritis of the Knee or Hip

    • Michael D. Levin
    Ann Intern Med December 18, 2007 147:884

  • Chondroitin for Osteoarthritis of the Knee or Hip

    • Sven Trelle,
    • Stephan Reichenbach,
    • and Peter Jüni
    Ann Intern Med December 18, 2007 147:884-885

  • Very Late Restenosis after Paclitaxel-Eluting Stent Implantation

    • John Cosgrave,
    • Asif Qasim,
    • Azeem Latib,
    • Tiziana Claudia Aranzulla,
    • and Antonio Colombo
    Ann Intern Med December 18, 2007 147:885-887

  • Correction: Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

    Ann Intern Med December 18, 2007 147:887

Ad Libitum

Thanks to Reviewers

Medical Notices

  • Medical Notices

    Ann Intern Med December 18, 2007 147:0

Summaries for Patients

  • Screening for Blockages in the Blood Vessels to the Brain: Recommendations from the U.S. Preventive Services Task Force

    Ann Intern Med December 18, 2007 147:I-36
« Previous | Next Issue »

This Issue

December 18, 2007; 147 (12)
  1. Articles
  2. Academia and Clinic
  3. Review
  4. Clinical Guidelines
  5. Editorial
  6. Letters
  7. Ad Libitum
  8. Thanks to Reviewers
  9. Medical Notices
  10. Summaries for Patients

Search in this issue:

Current Issue

  1. November 17, 2009, 151 (10)
  1. Alert me to current issues